Next Article in Journal
Aspects of Newborn Screening in Isovaleric Acidemia
Previous Article in Journal
Early Detection and Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Missed by Newborn Screening Using Tandem Mass Spectrometry
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2018, 4(1), 6; https://doi.org/10.3390/ijns4010006

Duchenne Muscular Dystrophy Newborn Screening, a Case Study for Examining Ethical and Legal Issues for Pilots for Emerging Disorders: Considerations and Recommendations

1
Parent Project Muscular Dystrophy, 401 Hackensack Avenue, 9th Floor, Hackensack, NJ 07601, USA
2
Departments of Neurology and Pediatrics, Johns Hopkins University, Baltimore, MD 21218, USA
3
American College of Medical Genetics and Genomics, Bethesda, MD 20814, USA
4
Muscular Dystrophy Association, Washington, DC 20006, USA
5
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
6
Departments of Law and Medicine (Obstetrics and Gynecology), University of Michigan, Ann Arbor, MI 48109, USA
7
Department of Bioethics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
8
Miller School of Medicine, Hussman Institute for Human Genomics, University of Miami, Miami, FL 33136, USA
*
Author to whom correspondence should be addressed.
Received: 12 December 2017 / Revised: 3 January 2018 / Accepted: 19 January 2018 / Published: 25 January 2018
View Full-Text   |   Download PDF [858 KB, uploaded 25 January 2018]   |  

Abstract

Duchenne muscular dystrophy (DMD/Duchenne) is one of the ten most severe and common pediatric genetic diseases and affects an estimated 1 in every 5000 male births. While Duchenne is a 100% fatal disease, the clinical community has demonstrated that immediate identification and early clinical interventions can add years, even decades to an individual’s life span. In anticipation of the changing therapeutic landscape for the Duchenne community, Parent Project Muscular Dystrophy established a newborn screening (NBS) initiative. This initiative included a Bioethics and Legal Issues Workgroup to consider the bioethics and legal issues of NBS for Duchenne. The workgroup’s discussion focused only on Duchenne NBS and met through conference calls over a one-year period of time seeking consensus on various identified issues. This article reports on the findings and recommendations from that workgroup. View Full-Text
Keywords: Duchenne; muscular dystrophy; newborn screening; carrier; X-linked disease Duchenne; muscular dystrophy; newborn screening; carrier; X-linked disease
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lloyd-Puryear, M.A.; Crawford, T.O.; Brower, A.; Stephenson, K.; Trotter, T.; Goldman, E.; Goldenberg, A.; Howell, R.R.; Kennedy, A.; Watson, M. Duchenne Muscular Dystrophy Newborn Screening, a Case Study for Examining Ethical and Legal Issues for Pilots for Emerging Disorders: Considerations and Recommendations. Int. J. Neonatal Screen. 2018, 4, 6.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top